Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity

Hybridoma

Volumn 16, Issue 1, 1997, Pages 23-26

  Durrant, L G ^a   Buckley, D J ^a   Spendlove, I ^a   Robins, R A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 105AD7; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DOSE RESPONSE; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE TRANSFORMATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0030938345     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1997.16.23     Document Type: Conference Paper

References (14)

1. Austin EB, Robins RA, Durrant LG, Price MR, and Baldwin RW: Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 79IT/36. Immunology 1989;67:525-530.
2. Robins RA, Denton GWL, Hardcastle JD, Austin EB, Baldwin RW, and Durrant LG: Antitumor immune-response and interleukin-2 production induced in colorectal-cancer patients by immunization with human monoclonal antiidiotypic antibody. Cancer Res 1991;51:5425-5429.
3. Durrant LG, Buckley DTJ, Spendlove I, and Robins RA: Monoclonal antibodies as cancer vaccines. Ann Oncol 1996 (in press).
4. Denton GWL, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, and Robins RA: Clinical outcome of colorectal-cancer patients treated with human monoclonal antiidiotypic antibody. Int J Cancer 1994;57:10-14.
5. Durrant LG, Buckley TJD, Denton GWL, Hardcastle HD, Sewell HF, and Robins RA: Enhanced cell mediated tumour killing in pa-tients immunised with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res 1994;54:4837-4840.
6. Antibodies. WPotCUo Operation Manual for Control of Production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Br J Cancer 1986;54:557-568.
7. Sarzotti M, Robbins DS, and Hoffman PM: Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 1996;271:1726-1730.
8. Fagerberg J, Steinitz M, Wigzell H, Askelof P, and Mellstedt H: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigens in patients. Proc Natl Acad Sci USA 1995;92:l-5.
9. Mittelman A, Chen ZJ, Yang H, Wong GY, and Ferrone S: Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival of patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-470.
10. Foon KA, Chakraborty M, John WJ, Sharratt A, Kohler H, and Bhattaoharya-Chatterjee M: Immune response to the carcinoem-bryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995;96:334-342.
11. Austin EB, Robins RA, Baldwin RW, and Durrant LG: Induction of delayed-hypersensitivity to human tumor-cells with a human monoclonal antiidiotypic antibody. J. Natl Cancer Inst 1991;83:1245-1248.
12. Durrant LG, Doran M, Austin EB, and Robins RA: Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int J Cancer 1995;61:62-66.
13. Buckley DTJ, Robins RA, and Durrant LG: Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumour T cell responses. Hum Antibody Hybridoma 1995;6:68-72.
14. Durrant LG, Spendlove I, and Robins RA: The human anti-idiotypic antibody 105AD7 has multiple class I and Class II motifs within the CDRH3 which correlate with helper and CTL responses induced in immunised patients. Cancer Res 1996;37:3190-3190.